Alan K. Burnett

H, Eath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 133 publications

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.

Journal: Blood
Published: August 19, 2025

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Journal: Blood
Published: August 19, 2025

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.

Journal: Blood
Published: April 18, 2025

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.

Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.

Journal: Leukemia
Published: February 07, 2025

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

Journal: The Lancet. Haematology
Published: May 01, 2024

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.

Journal: Blood
Published: February 27, 2024

How Long Does Contouring Really Take? Results of the Royal College of Radiologists Contouring Surveys.

How Long Does Contouring Really Take? Results of the Royal College of Radiologists Contouring Surveys.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: February 15, 2024

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Journal: Blood
Published: November 03, 2023

Prognostic impact of CEBPA mutational subgroups in adult AML.

Prognostic impact of CEBPA mutational subgroups in adult AML.

Journal: Leukemia
Published: October 30, 2023

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Journal: British journal of haematology
Published: September 01, 2023

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.

Journal: Leukemia & lymphoma
Published: October 13, 2022

A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.

A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial.

Journal: British journal of haematology
Published: August 24, 2022
Showing 1-12 of 133

Last Updated: 09/26/2026